Oral oncology最新文献

{"title":"Commentary on, “Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.”","authors":"Gnanaprakash Jeyara","doi":"10.1016/j.oraloncology.2025.107320","DOIUrl":"10.1016/j.oraloncology.2025.107320","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107320"},"PeriodicalIF":4.0,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer","authors":"Christopher M.K.L. Yao ,&nbsp;Katrina Hueniken ,&nbsp;Shao Hui Huang ,&nbsp;Geoffrey Liu ,&nbsp;Scott Bratman ,&nbsp;Andrew Hope ,&nbsp;Andrew McPartlin ,&nbsp;Jillian C. Tsai ,&nbsp;Sharon Tzelnik ,&nbsp;David Goldstein ,&nbsp;Ali Hosni ,&nbsp;Timothy C.Y. Chan ,&nbsp;John R. de Almeida","doi":"10.1016/j.oraloncology.2025.107304","DOIUrl":"10.1016/j.oraloncology.2025.107304","url":null,"abstract":"<div><h3>Introduction</h3><div>Recurrence rates among Head and Neck Cancer (HNC) patients are high, with earlier detection associated with improved survival. Patient-reported outcomes (PROs) have increasingly been found to predict patient care needs. Here, we examine whether PROs specific to HNC patients or general can predict disease progression using Machine Learning (ML) algorithms.</div></div><div><h3>Methods</h3><div>This was an analysis of 1,302 HNC patients,<!--> <!-->including patients who completed at least one MD Anderson Symptom Inventory (MDASI) or Edmonton Symptom Assessment Score (ESAS) questionnaire 3 months following curative intent treatment. ML models, including least absolute shrinkage and selection operator (LASSO) logistic regression and Random Forest (RF) were applied to baseline or longitudinal PRO changes to predict recurrences. Predictive performances were assessed via area under the receiver-operating curve, computed with 10-fold cross-validation. Relative variable importance were computed with average decrease in out-of-bag prediction accuracy of each tree.</div></div><div><h3>Results</h3><div>Disease recurrence occurred in 9.5 % (n = 123) of HNC patients. Baseline post-treatment MDASI, RF models demonstrated an area under the curve (AUC) approximating 0.675, sensitivity of 0.83 and specificity of 0.58 with pain, speech, and dry mouth as key variables. When stratifying patients by HPV status, our non-HPV model based on pain, distress, and mood yielded an AUC of 0.71 at 3 months and 0.70 at 6 months.</div></div><div><h3>Conclusion</h3><div>ML models using HNC specific PROs can identify patients at high risk for disease progression with moderate accuracy. Prospective studies with larger dataset and further analysis are needed to refine these models and evaluate their potential in guiding post-treatment surveillance.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107304"},"PeriodicalIF":4.0,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer","authors":"Andrea Costantino ,&nbsp;Claudio Sampieri ,&nbsp;Bruce H. Haughey ,&nbsp;Uthman Alamoudi ,&nbsp;Armando De Virgilio ,&nbsp;J. Scott Magnuson","doi":"10.1016/j.oraloncology.2025.107312","DOIUrl":"10.1016/j.oraloncology.2025.107312","url":null,"abstract":"<div><h3>Objectives</h3><div>Older adults are an increasing proportion of patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC), and transoral surgery (TOS) remains a valid treatment option for this population. This study aimed to evaluate the impact of adjuvant therapy on survival outcomes in this group.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed data from the National Cancer Database (NCDB) for older adults (≥65 years) diagnosed with OPSCC and treated with primary TOS. Patients were stratified into low, intermediate, and high-risk groups according to specific pathological criteria. The survival benefit of adjuvant therapy was assessed using a multivariable Cox regression model.</div></div><div><h3>Results</h3><div>A total of 998 patients undergoing primary TOS for HPV-related OPSCC were classified in low (N = 347, 34.8 %), intermediate (N = 261, 26.1 %) and high (N = 390, 39.1 %) risk groups. Adjuvant treatment showed no significant benefit in the low (adjusted HR: 0.70; 95 % CI: 0.33–1.47) and intermediate (HR: 0.73; 95 % CI: 0.36–1.48) risk groups. Adjuvant treatment was beneficial in the high risk group (adjusted HR: 0.40, 95 % CI: 0.25–0.62), with adjuvant chemoradiotherapy (adjusted HR: 0.28 95 % CI: 0.16–0.48; p &lt; 0.001) showing a slight advantage compared to radiotherapy alone (adjusted HR: 0.61, 95 % CI: 0.36–1.03).</div></div><div><h3>Conclusion</h3><div>The findings suggest that adjuvant therapy should be selectively applied in older adults with OPSCC, with a significant survival benefit observed primarily in high-risk patients. Future studies are needed to confirm the safety and efficacy of treatment de-escalation strategies in this population.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107312"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Rhabdomyosarcoma of head and neck varies in aggressiveness depending on the specific site of origin.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107318","DOIUrl":"10.1016/j.oraloncology.2025.107318","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107318"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An elderly man with tongue swelling and dysphagia","authors":"Jie Deng,&nbsp;Kexiong Ouyang,&nbsp;Chuandong Zhu","doi":"10.1016/j.oraloncology.2025.107313","DOIUrl":"10.1016/j.oraloncology.2025.107313","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107313"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","authors":"Satoshi Kano ,&nbsp;Daisuke Kawakita ,&nbsp;Yoshitaka Honma ,&nbsp;Hideaki Takahashi ,&nbsp;Masato Nakaguro ,&nbsp;Yoshitaka Utsumi ,&nbsp;Natsuki Saigusa ,&nbsp;Toyoyuki Hanazawa ,&nbsp;Kiyoaki Tsukahara ,&nbsp;Takuro Okada ,&nbsp;Kenji Okami ,&nbsp;Keisuke Yamazaki ,&nbsp;Yushi Ueki ,&nbsp;Yuki Saito ,&nbsp;Hiroyuki Ozawa ,&nbsp;Tomoyuki Arai ,&nbsp;Akira Shimizu ,&nbsp;Kenji Hanyu ,&nbsp;Sho Iwaki ,&nbsp;Sae Imaizumi ,&nbsp;Yuichiro Tada","doi":"10.1016/j.oraloncology.2025.107280","DOIUrl":"10.1016/j.oraloncology.2025.107280","url":null,"abstract":"<div><h3>Objectives</h3><div>Recent advances in systemic therapy for salivary duct carcinoma (SDC) have been driven by the development of HER2- and androgen receptor (AR)-targeted therapies. Trastuzumab deruxtecan has proven effective not only in HER2-positive but also HER2-low breast and gastro-esophageal cancers. However, the significance of HER2-low expression in SDC remains unknown. This study aimed to investigate the clinicopathologic characteristics, prognostic implications, and impact on efficacy to AR-targeted therapy in HER2-low SDC.</div></div><div><h3>Materials and Methods</h3><div>This was a multi-center, observational study. HER2 status was reclassified as follows: HER2-positive (IHC3+ or 2+/ISH+ ), HER2-low (IHC1+ or 2+/ISH-), and HER2-zero (IHC0). The subjects were compared in three groups: total population, curative treatment cohort, and AR-targeted therapy cohort.</div></div><div><h3>Results</h3><div>The total population consisted of 526 patients, of whom, 271 (52 %), 184 (35 %), and 71 (13 %) had HER2-positive, -low, and -zero tumors, respectively. Sex, M category, histological origin, Ki67, and p53 expression differed significantly between the HER2-low and HER2-positive cases. No differences in relapse-free or overall survival were observed for HER2 status in the curative treatment cohort; however, in the AR-targeted therapy cohort, the HER2-low group had significantly better response rates (41.6 % vs. 18.9 %, Odds ratio = 0.30, <em>P</em> = 0.012) and longer median progression-free survival (6.9 vs. 4.2 months, Hazard ratio = 1.61, <em>P</em> = 0.029) than those of the HER2-positive group.</div></div><div><h3>Conclusion</h3><div>HER2-low showed different clinicopathologic features from HER2-positive cases, with no prognostic differences observed in patients who underwent curative treatment. Still, HER2-low may be associated with the efficacy of AR-targeted therapy.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107280"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Histopathological invasion patterns and prognosis in oral squamous cell carcinoma: A retrospective analysis of 560 cases”","authors":"Qi Xu,&nbsp;Yuwan Gao","doi":"10.1016/j.oraloncology.2025.107314","DOIUrl":"10.1016/j.oraloncology.2025.107314","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107314"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge","authors":"Ping Zhou ,&nbsp;Yingming Zhu ,&nbsp;Baolei Xu ,&nbsp;Xiao Jiang ,&nbsp;Wei Wang ,&nbsp;Ye Zhang","doi":"10.1016/j.oraloncology.2025.107316","DOIUrl":"10.1016/j.oraloncology.2025.107316","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma(NPC) is an epithelial malignancy of the nasopharyngeal mucosa. It typically exhibits local infiltration with frequent skull base involvement and often presents with multiple cranial neuropathies. It can invade the cavernous sinus via the skull base and foramen ovals, thereby causing cavernous sinus syndrome (CSS). When NPC invades nerves, the mass in the nasopharyngeal cavity may not be obvious. We report a case of CSS presenting as painful ophthalmoplegia or nonspecific inflammation. While initial glucocorticoid therapy provided transient symptom relief, the patient developed progressive neurological deficits. Ultimately, nasopharyngoscopic biopsy confirmed NPC through histopathological verification.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107316"},"PeriodicalIF":4.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma","authors":"Revadhi C Chelvarajah ,&nbsp;Ye Liu ,&nbsp;Jie Su ,&nbsp;Ali Hosni Abdalaty ,&nbsp;Scott Bratman ,&nbsp;B.C. John Cho ,&nbsp;Ezra Hahn ,&nbsp;Andrew Hope ,&nbsp;John Kim ,&nbsp;Brian O’Sullivan ,&nbsp;Jolie Ringash ,&nbsp;C. Jillian Tsai ,&nbsp;John Waldron ,&nbsp;Anna Spreafico ,&nbsp;Enrique Sanz Garcia ,&nbsp;David Goldstein ,&nbsp;Christopher Yao ,&nbsp;Li Tong ,&nbsp;Shao Hui Huang ,&nbsp;Andrew McPartlin","doi":"10.1016/j.oraloncology.2025.107310","DOIUrl":"10.1016/j.oraloncology.2025.107310","url":null,"abstract":"<div><h3>Purpose/Background</h3><div>We aim to describe characteristics and patterns of detection of distant metastasis (DM) and subsequent outcomes following definitive (chemo)radiotherapy [(C)RT] for oropharyngeal cancer (OPC).</div></div><div><h3>Material/Methods</h3><div>OPC patients who developed DM after initial complete response to (C)RT from 2010 to 2020 were included. DM were classified as oligometastases (≤5 lesions) vs polymetastases. Interval from prior normal surveillance imaging to DM detection was recorded. Multivariable analysis (MVA) was performed for overall survival (OS) after DM.</div></div><div><h3>Results</h3><div>A total of 124 patients were eligible. Most (116/124, 94 %) developed DMs within the thorax, of whom 72 (58 %) had thorax only DM. Oligometastases (n = 46) vs polymetastases (n = 78) were more commonly detected without DM-related symptoms (76 % vs 55 %, p = 0.003) and identified with shorter interval from previous normal imaging (median 7.9 vs 12.7 months, p = 0.030). Median follow-up from DM diagnosis was 31.5 months. Three-year OS after DM was higher for patients with oligometastases vs polymetastases (32 % vs 5 %, p &lt; 0.001). Patients with oligometastases who received salvage therapy had a longer 3-year OS (vs not) (63 % vs 7 %, p &lt; 0.001). On MVA, salvage therapy (Hazard Ratio [HR) 0.32, p = 0.005), HPV + status (HR 0.50, p = 0.002) and thorax only distant metastases (HR 0.64, p = 0.034) were associated with longer OS.</div></div><div><h3>Conclusions</h3><div>Nearly one-third of first DM in OPC following initial complete response to (C)RT are oligometastases and most occur within the thorax. Most oligometastases are asymptomatic and more commonly detected following a shorter surveillance scan interval. DM-targeted salvage therapy for oligometastases is associated with longer OS. Prospective studies refining surveillance algorithms to increase detection of oligometastases in asymptomatic high-risk OPC patients are indicated.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107310"},"PeriodicalIF":4.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to Editor on, “Impact of radiation dose to the swallowing organs on death from aspiration pneumonia in oral cavity cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107319","DOIUrl":"10.1016/j.oraloncology.2025.107319","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107319"},"PeriodicalIF":4.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}